{"id":"intravitreal-bevacizumab-ivb","safety":{"commonSideEffects":[{"rate":null,"effect":"Endophthalmitis"},{"rate":null,"effect":"Retinal detachment"},{"rate":null,"effect":"Cataract progression"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Floaters/vitreous opacities"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Intravitreal bevacizumab works by binding to and neutralizing VEGF, a key driver of pathological neovascularization in retinal diseases. By reducing VEGF signaling, it suppresses the growth of abnormal blood vessels and reduces vascular permeability, thereby reducing retinal edema and preventing vision loss in conditions characterized by excessive angiogenesis.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:29.658Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration (AMD), wet form"},{"name":"Diabetic macular edema (DME)"},{"name":"Retinal vein occlusion (RVO)"},{"name":"Proliferative diabetic retinopathy (PDR)"}]},"trialDetails":[{"nctId":"NCT06882551","phase":"PHASE4","title":"Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients","status":"COMPLETED","sponsor":"Khyber Teaching Hospital","startDate":"2023-04-01","conditions":"Diabetic Macular Edema (DME)","enrollment":82},{"nctId":"NCT06559488","phase":"NA","title":"IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2018-04-02","conditions":"Diabetic Retinopathy, Vitreous Hemorrhage","enrollment":18},{"nctId":"NCT05514925","phase":"PHASE4","title":"Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy","status":"UNKNOWN","sponsor":"Khairallah Moncef","startDate":"2017-11-21","conditions":"Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment","enrollment":60},{"nctId":"NCT02985619","phase":"PHASE2, PHASE3","title":"Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2016-07-21","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT04800679","phase":"PHASE2","title":"Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-03-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":105},{"nctId":"NCT04511715","phase":"PHASE2, PHASE3","title":"Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-09-01","conditions":"Non-proliferative Diabetic Retinopathy","enrollment":100},{"nctId":"NCT02229175","phase":"PHASE2, PHASE3","title":"Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2021-01-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00548197","phase":"PHASE1","title":"Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment","status":"COMPLETED","sponsor":"Iran University of Medical Sciences","startDate":"2007-02","conditions":"Intravitreal Bevacizumab Injection, Pars Plana Vitrectomy, Tractional Retinal Detachment","enrollment":40},{"nctId":"NCT00802126","phase":"PHASE1","title":"Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2007-11","conditions":"Myopia","enrollment":16},{"nctId":"NCT00745498","phase":"NA","title":"Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2008-06","conditions":"Proliferative Diabetic Retinopathy, Vitreous Hemorrhage","enrollment":126},{"nctId":"NCT02310295","phase":"NA","title":"Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-01","conditions":"Diabetic Macular Edema","enrollment":45},{"nctId":"NCT01504724","phase":"PHASE4","title":"Effect of the Adjunctive IVB Before PRP","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2011-08","conditions":"Diabetic Retinopathy","enrollment":30},{"nctId":"NCT01439178","phase":"NA","title":"Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2011-08","conditions":"Complications of Diabetes Mellitus","enrollment":28},{"nctId":"NCT01141881","phase":"NA","title":"Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema","status":"TERMINATED","sponsor":"Mashhad University of Medical Sciences","startDate":"2009-05","conditions":"Diabetic Macular Edema","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intravitreal Bevacizumab IVB","genericName":"Intravitreal Bevacizumab IVB","companyName":"Khyber Teaching Hospital","companyId":"khyber-teaching-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye. Used for Age-related macular degeneration (AMD), wet form, Diabetic macular edema (DME), Retinal vein occlusion (RVO).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}